Murray T S
Department of General Practice, University of Glasgow.
Br J Clin Pract. 1996 Oct-Nov;50(7):368-72.
The efficacy and tolerability of nisoldipine coat-core (nisoldipine CC 10, 20, 40 mg) and atenolol (50, 100 mg) were compared in 230 patients with mild to moderate essential hypertension. Treatment was titrated at two-weekly intervals as necessary to control blood pressure. After eight weeks of active therapy, the two treatments proved to be equally effective in reducing sitting diastolic blood pressure (13.7 +/- 8.3 mmHg and 14.2 +/- 9.1 mmHg for nisoldipine CC and atenolol, respectively), and provided equivalent reduction in systolic blood pressure and identical response rates (69%). Heart rate was reduced from baseline in the atenolol group but remained unchanged in the nisoldipine CC group (p < 0.001 difference between the two groups). Both nisoldipine CC and atenolol were well tolerated and had no detectable metabolic effects. Adverse events were minor and of the type commonly associated with drugs of these classes.
对230例轻至中度原发性高血压患者比较了尼索地平包芯片(尼索地平CC 10、20、40毫克)和阿替洛尔(50、100毫克)的疗效和耐受性。必要时每两周调整一次治疗剂量以控制血压。经过八周的积极治疗,两种治疗方法在降低坐位舒张压方面被证明同样有效(尼索地平CC和阿替洛尔分别为13.7±8.3毫米汞柱和14.2±9.1毫米汞柱),并在收缩压降低方面提供了等效效果且应答率相同(69%)。阿替洛尔组心率从基线水平降低,但尼索地平CC组心率保持不变(两组间差异p<0.001)。尼索地平CC和阿替洛尔耐受性均良好,且未发现代谢影响。不良事件轻微,且属于这些类药物常见的类型。